intolerance of or allergy to ticagrelor or prasugrel
history of any stroke, transient ischemic attack or intracranial bleeding
known intracranial neoplasm, intracranial arteriovenous malformation or intracranial aneurysm
active bleeding, clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding
fibrin-specific fibrinolytic therapy less than 24 h before randomization, non-fibrin-specific fibrinolytic therapy less than 48 h before randomization
known platelet count < 100.000/µL at the time of screening
known anemia (hemoglobin <10 g/dL) at the time of screening
oral anticoagulation that cannot be safely discontinued for the duration of the study
INR known to be greater than 1.5 at the time of screening
chronic renal insufficiency requiring dialysis
moderate or severe hepatic dysfunction (Child Pugh B or C)
increased risk of bradycardia events (Sick Sinus, AV block grade II or III, bradycardia-induced syncope)
index event is an acute complication (< 30 days) of PCI
concomitant medical illness that in the opinion of the investigator is associated with a life expectancy < 1 year
concomitant oral or i.v. therapy with strong CYP3A Inhibitors (e.g. ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice > 1 L/d), CYP3A substrates with narrow therapeutic indices (e.g. cyclosporine, quinidine), or strong CYP3A inducers (e.g. rifampin/rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital ) that cannot be safely discontinued
=1 doses of ticagrelor or prasugrel within 5 days before randomisation
no written informed consent
participation in another investigational drug study
previous enrolment in this study
for women of childbearing potential no negative pregnancy test and no agree to use reliable method of birth control during the study
Pregnancy, giving birth within the last 90 days, or lactation
inability to cooperate with protocol requirements

NCT01944800_inc_T1
Drug
ticagrelor
NCT01944800_inc_T2
Condition
intolerance
NCT01944800_inc_T3
Condition
allergy
NCT01944800_inc_T4
Drug
prasugrel
NCT01944800_inc_T5
Scope
ticagrelor or prasugrel
NCT01944800_inc_T6
Scope
intolerance of or allergy
NCT01944800_inc_T7
Condition
stroke
NCT01944800_inc_T8
Condition
transient ischemic attack
NCT01944800_inc_T9
Condition
intracranial bleeding
NCT01944800_inc_T10
Condition
intracranial neoplasm
NCT01944800_inc_T11
Condition
intracranial arteriovenous malformation
NCT01944800_inc_T12
Condition
intracranial aneurysm
NCT01944800_inc_T13
Condition
bleeding
NCT01944800_inc_T14
Temporal
active
NCT01944800_inc_T15
Condition
clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding
NCT01944800_inc_T16
Scope
bleeding, clinical findings, that in the judgement of the investigator are associated with an increased risk of bleeding
NCT01944800_inc_T17
Procedure
fibrinolytic therapy
NCT01944800_inc_T18
Qualifier
fibrin-specific
NCT01944800_inc_T19
Temporal
less than 24 h before randomization
NCT01944800_inc_T20
Procedure
fibrinolytic therapy
NCT01944800_inc_T21
Qualifier
non-fibrin-specific
NCT01944800_inc_T22
Temporal
less than 48 h before randomization
NCT01944800_inc_T23
Measurement
platelet count
NCT01944800_inc_T24
Value
< 100.000/µL
NCT01944800_inc_T25
Temporal
at the time of screening
NCT01944800_inc_T26
Reference_point
randomization
NCT01944800_inc_T27
Reference_point
randomization
NCT01944800_inc_T28
Reference_point
the time of screening
NCT01944800_inc_T29
Condition
anemia
NCT01944800_inc_T30
Measurement
hemoglobin
NCT01944800_inc_T31
Value
<10 g/dL
NCT01944800_inc_T32
Temporal
at the time of screening
NCT01944800_inc_T33
Reference_point
the time of screening
NCT01944800_inc_T34
Procedure
oral anticoagulation
NCT01944800_inc_T35
Qualifier
cannot be safely discontinued
NCT01944800_inc_T36
Temporal
for the duration of the study
NCT01944800_inc_T37
Reference_point
the study
NCT01944800_inc_T38
Measurement
INR
NCT01944800_inc_T39
Value
greater than 1.5
NCT01944800_inc_T40
Temporal
at the time of screening
NCT01944800_inc_T41
Reference_point
the time of screening
NCT01944800_inc_T42
Condition
chronic renal insufficiency
NCT01944800_inc_T43
Procedure
dialysis
NCT01944800_inc_T44
Condition
hepatic dysfunction
NCT01944800_inc_T45
Qualifier
severe
NCT01944800_inc_T46
Qualifier
moderate
NCT01944800_inc_T47
Scope
moderate or severe
NCT01944800_inc_T48
Measurement
Child Pugh
NCT01944800_inc_T49
Value
B or C
NCT01944800_inc_T50
Condition
bradycardia events
NCT01944800_inc_T51
Mood
increased risk
NCT01944800_inc_T52
Condition
Sick Sinus
NCT01944800_inc_T53
Condition
AV block
NCT01944800_inc_T54
Measurement
grade
NCT01944800_inc_T55
Value
II or III
NCT01944800_inc_T56
Condition
bradycardia-induced syncope
NCT01944800_inc_T57
Scope
Sick Sinus, AV block grade II or III, bradycardia-induced syncope
NCT01944800_inc_T58
Condition
 (< 30 days mitant
NCT01944800_inc_T59
Value
< 30 days
NCT01944800_inc_T60
Qualifier
acute
NCT01944800_inc_T61
Condition
concomitant medical illness
NCT01944800_inc_T62
Qualifier
is associated with a life expectancy < 1 year
NCT01944800_inc_T63
Procedure
hera trong C
NCT01944800_inc_T64
Procedure
i.v. therapy
NCT01944800_inc_T65
Drug
strong CYP3A Inhibitors
NCT01944800_inc_T66
Drug
ketoconazole
NCT01944800_inc_T67
Drug
itraconazole
NCT01944800_inc_T68
Drug
voriconazole
NCT01944800_inc_T69
Drug
telithromycin
NCT01944800_inc_T70
Drug
clarithromycin
NCT01944800_inc_T71
Drug
nefazodone
NCT01944800_inc_T72
Drug
ritonavir
NCT01944800_inc_T73
Drug
saquinavir
NCT01944800_inc_T74
Drug
nelfinavir
NCT01944800_inc_T75
Drug
indinavir
NCT01944800_inc_T76
Drug
atazanavir
NCT01944800_inc_T77
Drug
grapefruit juice
NCT01944800_inc_T78
Multiplier
> 1 L/d
NCT01944800_inc_T79
Scope
ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice > 1 L/d
NCT01944800_inc_T80
Scope
oral or i.v. therapy
NCT01944800_inc_T81
Multiplier
=1 doses
NCT01944800_inc_T82
Drug
ticagrelor
NCT01944800_inc_T83
Drug
prasugrel
NCT01944800_inc_T84
Temporal
within 5 days before randomisation
NCT01944800_inc_T85
Reference_point
randomisation
NCT01944800_inc_T86
Scope
ticagrelor or prasugrel
NCT01944800_inc_T93
Drug
CYP3A substrates with narrow therapeutic indices
NCT01944800_inc_T94
Drug
cyclosporine
NCT01944800_inc_T95
Drug
quinidine
NCT01944800_inc_T96
Drug
strong CYP3A inducers
NCT01944800_inc_T97
Drug
rifampin
NCT01944800_inc_T98
Drug
rifampicin
NCT01944800_inc_T99
Drug
phenytoin
NCT01944800_inc_T100
Drug
carbamazepine
NCT01944800_inc_T101
Drug
dexamethason
NCT01944800_inc_T102
Drug
phenobarbital
NCT01944800_inc_T103
Scope
rifampin/rifampicin, phenytoin, carbamazepine, dexamethason, phenobarbital
NCT01944800_inc_T104
Scope
cyclosporine, quinidine